文献速递心脑血管急症消化、代谢与肾脏急症

齐贝西兰附加治疗用于控制不佳的高血压:KARDIA-2随机临床试验

Add-On Treatment With Zilebesiran for Inadequately Controlled Hypertension: The KARDIA-2 Randomized Clinical Trial.
PubMed 文献 · JAMA · 2025-01-01
一句话结论在已用吲达帕胺、氨氯地平或奥美沙坦仍未控制的高血压患者中,加用单次皮下齐贝西兰600 mg较安慰剂显著降低3个月24小时动态收缩压。

KARDIA-2为2期、随机、前瞻性、双盲试验,自8国150个中心纳入未控制高血压成人,先开放导入吲达帕胺2.5 mg、氨氯地平5 mg或奥美沙坦40 mg每日一次至少4周,达标者按1:1随机加用单次皮下齐贝西兰600 mg或安慰剂。3个月时24小时动态收缩压较基线变化,齐贝西兰较安慰剂在吲达帕胺组差值为-12.1 mm Hg(95%CI -16.5至-7.6;P<.001),氨氯地平组-9.7 mm Hg(95%CI -12.9至-6.6;P<.001),奥美沙坦组-4.5 mm Hg(95%CI -8.2至-0.8;P=.02)。齐贝西兰组高钾血症、低血压和急性肾衰竭事件例数多于安慰剂组,但多数轻微且无需医疗干预即缓解。

要点

  • 在吲达帕胺2.5 mg每日一次基础上加用单次皮下齐贝西兰600 mg,3个月24小时动态收缩压较安慰剂降低12.1 mm Hg(95%CI -16.5至-7.6)。
  • 在氨氯地平5 mg每日一次基础上加用齐贝西兰600 mg,3个月24小时动态收缩压较安慰剂降低9.7 mm Hg(95%CI -12.9至-6.6)。
  • 在奥美沙坦40 mg每日一次基础上加用齐贝西兰600 mg,3个月24小时动态收缩压较安慰剂降低4.5 mm Hg(95%CI -8.2至-0.8)。
  • 齐贝西兰组高钾血症18例(5.5%)vs 安慰剂6例(1.8%)、低血压14例(4.3%)vs 7例(2.1%)、急性肾衰竭16例(4.9%)vs 5例(1.5%),多数轻微且无需医疗干预即缓解。

适用人群与场景

  • 8国150个中心纳入的成人未控制高血压患者,先接受开放导入吲达帕胺2.5 mg、氨氯地平5 mg或奥美沙坦40 mg每日一次至少4周。
  • 导入后24小时平均动态收缩压130 mm Hg至160 mm Hg且依从的患者随机加用盲法齐贝西兰600 mg或安慰剂。

诊断标准与关键阈值

  • 导入治疗后24小时平均动态收缩压130 mm Hg至160 mm Hg为随机分组条件。

处置流程与药物剂量

  • 先开放导入吲达帕胺2.5 mg、氨氯地平5 mg或奥美沙坦40 mg,均为每日一次,至少4周。
  • 导入后符合24小时平均动态收缩压130 mm Hg至160 mm Hg者,按1:1随机接受单次皮下齐贝西兰600 mg或匹配安慰剂。

研究设计与关键结果

  • 2期、随机、前瞻性、双盲试验,8国150个中心,1491例进入导入期,663例随机(齐贝西兰n=332,安慰剂n=331),其中吲达帕胺组130例、氨氯地平组240例、奥美沙坦组293例。
  • 主要终点3个月24小时平均动态收缩压较基线变化,齐贝西兰较安慰剂的组间最小二乘均值差值:吲达帕胺组-12.1 mm Hg(95%CI -16.5至-7.6;P<.001),氨氯地平组-9.7 mm Hg(95%CI -12.9至-6.6;P<.001),奥美沙坦组-4.5 mm Hg(95%CI -8.2至-0.8;P=.02)。
  • 不良事件:高钾血症齐贝西兰18例(5.5%)vs 安慰剂6例(1.8%),低血压14例(4.3%)vs 7例(2.1%),急性肾衰竭16例(4.9%)vs 5例(1.5%),多数轻微且无需医疗干预即缓解。

证据类型、等级与局限

  • 证据类型:2期随机、前瞻性、双盲临床试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于已用吲达帕胺2.5 mg、氨氯地平5 mg或奥美沙坦40 mg每日一次仍未控制的高血压患者,加用单次皮下齐贝西兰600 mg在3个月时较安慰剂显著降低24小时动态收缩压。
  • 使用齐贝西兰时需注意高钾血症、低血压和急性肾衰竭事件发生例数多于安慰剂,多数轻微且无需医疗干预即缓解。

指南或共识出处

  • KARDIA-2随机临床试验,ClinicalTrials.gov注册号NCT05103332。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: In prior monotherapy studies of patients with hypertension, single subcutaneous doses of zilebesiran, an investigational RNA interference therapeutic, reduced serum angiotensinogen levels and systolic blood pressure (SBP) at 3 and 6 months.

OBJECTIVE: To evaluate the efficacy and safety of zilebesiran vs placebo when added to a standard antihypertensive medication.

DESIGN, SETTING, AND PARTICIPANTS: This phase 2, randomized, prospective, double-blinded trial enrolled adults with uncontrolled hypertension from 150 sites across 8 countries between January 2022 and June 2023. The final follow-up date was December 11, 2023, and analyses were conducted on March 1, 2024.

INTERVENTIONS: Eligible patients were initially randomized in cohorts to receive open-label run-in treatment for at least 4 weeks with indapamide 2.5 mg, amlodipine 5 mg, or olmesartan 40 mg (4:7:10 randomization), each administered once daily. Within cohorts, adherent patients with 24-hour mean ambulatory SBP of 130 mm Hg to 160 mm Hg were subsequently randomized (1:1) to additional blinded treatment to receive single subcutaneous doses of zilebesiran 600 mg or matching placebo.

MAIN OUTCOMES AND MEASURES: The primary end point in each cohort was the difference between zilebesiran and placebo in change from baseline in 24-hour mean ambulatory SBP at 3 months.

RESULTS: Of 1491 patients entering the run-in phase, 663 (130 receiving indapamide, 240 receiving amlodipine, and 293 receiving olmesartan) were randomized to receive zilebesiran (n = 332) or placebo (n = 331). The least-squares mean difference between zilebesiran and placebo in change from baseline to 3 months in 24-hour mean ambulatory SBP was -12.1 mm Hg (95% CI, -16.5 to -7.6; P < .001) for indapamide, -9.7 mm Hg (95% CI, -12.9 to -6.6; P < .001) for amlodipine, and -4.5 mm Hg (95% CI, -8.2 to -0.8; P = .02) for olmesartan. Across cohorts, more patients who received zilebesiran than placebo experienced hyperkalemia (18 [5.5%] vs 6 [1.8%]), hypotension (14 [4.3%] vs 7 [2.1%]), and acute kidney failure (16 [4.9%] vs 5 [1.5%]) events, but most episodes were mild and resolved without medical intervention.

CONCLUSIONS AND RELEVANCE: In patients with uncontrolled hypertension despite treatment with indapamide, amlodipine, or olmesartan, the addition of single-dose zilebesiran resulted in significant SBP reductions compared with placebo at 3 months, with low rates of serious adverse events.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05103332.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Desai AS, Karns AD, Badariene J, et al. Add-On Treatment With Zilebesiran for Inadequately Controlled Hypertension: The KARDIA-2 Randomized Clinical Trial. JAMA. 2025. PMID: 40434761. doi:10.1001/jama.2025.6681

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。